We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App





Scientists Develop Microscopic Sponges That Soak Up and Neutralize Coronavirus

By HospiMedica International staff writers
Posted on 22 Jun 2020
Print article
Image: Nanosponges attacking and neutralizing the SARS-COV-2 virus (Photo courtesy of UC San Diego)
Image: Nanosponges attacking and neutralizing the SARS-COV-2 virus (Photo courtesy of UC San Diego)
Nanoparticles cloaked in human lung cell membranes and human immune cell membranes are capable of attracting and neutralizing the SARS-CoV-2 virus in cell culture, making the virus lose its ability to hijack host cells and reproduce.

The "nanosponges" were developed by engineers at the UC San Diego (La Jolla, CA, USA) and tested by researchers at Boston University (Boston, MA, USA), creating a new direction for fighting COVID-19. The researchers call their nano-scale particles "nanosponges" because they soak up harmful pathogens and toxins. Each COVID-19 nanosponge, which is a thousand times smaller than the width of a human hair, consists of a polymer core coated in cell membranes extracted from either lung epithelial type II cells or macrophage cells. The membranes cover the sponges with all the same protein receptors as the cells they impersonate—and this inherently includes whatever receptors SARS-CoV-2 uses to enter cells in the body.

The researchers prepared several different concentrations of nanosponges in solution to test against the novel coronavirus. In lab experiments, both the lung cell and immune cell types of nanosponges caused the SARS-CoV-2 virus to lose nearly 90% of its "viral infectivity" in a dose-dependent manner. Instead of targeting the virus itself, these nanosponges are designed to protect the healthy cells the virus invades. Additionally, the nanosponges cloaked with fragments of the outer membranes of macrophages could also be capable of soaking up inflammatory cytokine proteins, which are implicated in some of the most dangerous aspects of COVID-19 and are driven by immune response to the infection.

In the next few months, the researchers will evaluate the efficacy of these nanosponges in animal models. The researchers have already shown short-term safety in the respiratory tracts and lungs of mice, and hope to test these COVID-19 nanosponges in humans as early as possible. The researchers also expect these nanosponges would work against any new coronavirus or even other respiratory viruses, including whatever virus might trigger the next respiratory pandemic. Additionally, the research team plans to study whether the macrophage sponges also have the ability to quiet cytokine storms in COVID-19 patients. If the sponges reach the clinical trial stage, there are multiple potential ways of delivering the therapy that include direct delivery into the lung for intubated patients, via an inhaler like for asthmatic patients, or intravenously, especially to treat the complication of cytokine storm.

“Traditionally, drug developers for infectious diseases dive deep on the details of the pathogen in order to find druggable targets. Our approach is different. We only need to know what the target cells are. And then we aim to protect the targets by creating biomimetic decoys,” said Liangfang Zhang, a nanoengineering professor at the UC San Diego Jacobs School of Engineering. “Another interesting aspect of our approach is that even as SARS-CoV-2 mutates, as long as the virus can still invade the cells we are mimicking, our nanosponge approach should still work. I’m not sure this can be said for some of the vaccines and therapeutics that are currently being developed.”

Related Links:
UC San Diego
Boston University



Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
12-Channel ECG
CM1200B
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Bronchoscopy Head Support
Reison 10-330

Print article

Channels

Surgical Techniques

view channel
Image: LUMISIGHT and Lumicell DVS offer 84% diagnostic accuracy in detecting residual cancer (Photo courtesy of Lumicell)

Cutting-Edge Imaging Platform Detects Residual Breast Cancer Missed During Lumpectomy Surgery

Breast cancer is becoming increasingly common, with statistics indicating that 1 in 8 women will develop the disease in their lifetime. Lumpectomy remains the predominant surgical intervention for treating... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The Quantra Hemostasis System has received US FDA special 510(k) clearance for use with its Quantra QStat Cartridge (Photo courtesy of HemoSonics)

Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing

Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.